Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.70 |
| ▸ | EGFR | P00533 | 10/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650776 | 0.91 | AURKA (0.71) | KDREGFRAURKBAURKAMAPK14 | |
| SCHEMBL5025447 | 0.90 | KDR (0.71) | KDREGFRAURKBAURKAIRAK4 | |
| Hydrochloric Acid SCHEMBL5022938 | 0.89 | KDR (0.70) | KDREGFRAURKBAURKAIRAK4 | |
| SCHEMBL5022508 | 0.88 | KDR (0.69) | KDREGFRAURKBAURKAIRAK4 | |
| SCHEMBL5022330 | 0.88 | KDR (0.69) | KDREGFRAURKBAURKAMAPK14 | |
| SCHEMBL5025440 | 0.87 | KDR (0.67) | KDREGFRAURKBAURKAIRAK4 | |
| SCHEMBL5023471 | 0.87 | KDR (0.74) | KDREGFRAURKBAURKAMAPK14 | |
| SCHEMBL5022354 | 0.86 | KDR (0.66) | KDREGFRAURKBAURKAIRAK4 | |
| SCHEMBL5025477 | 0.85 | KDR (0.64) | KDREGFRAURKBAURKAMAPK14 | |
| SCHEMBL5090002 | 0.84 | KDR (0.63) | KDREGFRAURKBAURKAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575966-B1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-20060058325-A1 | Therapeutic quniazoline derivatives | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575966-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058782-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058325-A1 | Therapeutic quniazoline derivatives | NQO2, ABL1, CYP3A7 | KDR 3166/4885EGFR 2724/4885AURKB 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.